182 related articles for article (PubMed ID: 38713943)
21. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
22. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
23. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.
Negi CK; Babica P; Bajard L; Bienertova-Vasku J; Tarantino G
Metabolism; 2022 Jan; 126():154925. PubMed ID: 34740573
[TBL] [Abstract][Full Text] [Related]
24. Update of Indoles: Promising molecules for ameliorating metabolic diseases.
Hu W; Yan G; Ding Q; Cai J; Zhang Z; Zhao Z; Lei H; Zhu YZ
Biomed Pharmacother; 2022 Jun; 150():112957. PubMed ID: 35462330
[TBL] [Abstract][Full Text] [Related]
25. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.
Pafili K; Roden M
Mol Metab; 2021 Aug; 50():101122. PubMed ID: 33220492
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Application of Micellar Solubilized Xanthohumol in a Western-Type Diet-Induced Mouse Model of Obesity, Diabetes and Non-Alcoholic Fatty Liver Disease.
Mahli A; Seitz T; Freese K; Frank J; Weiskirchen R; Abdel-Tawab M; Behnam D; Hellerbrand C
Cells; 2019 Apr; 8(4):. PubMed ID: 30999670
[TBL] [Abstract][Full Text] [Related]
27. Kaempferol and atherosclerosis: From mechanism to medicine.
Chen M; Xiao J; El-Seedi HR; Woźniak KS; Daglia M; Little PJ; Weng J; Xu S
Crit Rev Food Sci Nutr; 2024; 64(8):2157-2175. PubMed ID: 36099317
[TBL] [Abstract][Full Text] [Related]
28. Managing metabolic diseases: The roles and therapeutic prospects of herb-derived polysaccharides.
Xu X; Wang L; Zhang K; Zhang Y; Fan G
Biomed Pharmacother; 2023 May; 161():114538. PubMed ID: 36931026
[TBL] [Abstract][Full Text] [Related]
29. Integrative transcriptomics and metabolomics explore the mechanism of kaempferol on improving nonalcoholic steatohepatitis.
Lu Y; Shao M; Xiang H; Zheng P; Wu T; Ji G
Food Funct; 2020 Nov; 11(11):10058-10069. PubMed ID: 33135718
[TBL] [Abstract][Full Text] [Related]
30. Hepatic TLR4 signaling in obese NAFLD.
Sharifnia T; Antoun J; Verriere TG; Suarez G; Wattacheril J; Wilson KT; Peek RM; Abumrad NN; Flynn CR
Am J Physiol Gastrointest Liver Physiol; 2015 Aug; 309(4):G270-8. PubMed ID: 26113297
[TBL] [Abstract][Full Text] [Related]
31. G protein-coupled estrogen receptor 1 ameliorates nonalcoholic steatohepatitis through targeting AMPK-dependent signaling.
Li L; Yao Y; Wang Y; Cao J; Jiang Z; Yang Y; Wang H; Ma H
J Biol Chem; 2024 Mar; 300(3):105661. PubMed ID: 38246352
[TBL] [Abstract][Full Text] [Related]
32. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
Patel Chavez C; Cusi K; Kadiyala S
J Clin Endocrinol Metab; 2022 Jan; 107(1):29-38. PubMed ID: 34406410
[TBL] [Abstract][Full Text] [Related]
33. Network pharmacology and molecular docking approaches to elucidate the potential compounds and targets of Saeng-Ji-Hwang-Ko for treatment of type 2 diabetes mellitus.
Ko M; Kim Y; Kim HH; Jeong S; Ahn D; Chung SJ; Kim H
Comput Biol Med; 2022 Oct; 149():106041. PubMed ID: 36049411
[TBL] [Abstract][Full Text] [Related]
34. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
[TBL] [Abstract][Full Text] [Related]
35. Metabolic Targets in Nonalcoholic Fatty Liver Disease.
Esler WP; Bence KK
Cell Mol Gastroenterol Hepatol; 2019; 8(2):247-267. PubMed ID: 31004828
[TBL] [Abstract][Full Text] [Related]
36. Kaempferol Suppresses Carbon Tetrachloride-Induced Liver Damage in Rats via the MAPKs/NF-κB and AMPK/Nrf2 Signaling Pathways.
Lee C; Yoon S; Moon JO
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108064
[TBL] [Abstract][Full Text] [Related]
37. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
38. Anthocyanins: Potential phytochemical candidates for the amelioration of non-alcoholic fatty liver disease.
Mandal B; Das R; Mondal S
Ann Pharm Fr; 2024 May; 82(3):373-391. PubMed ID: 38354975
[TBL] [Abstract][Full Text] [Related]
39. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
[TBL] [Abstract][Full Text] [Related]
40. Network pharmacology and molecular docking study on the effect of Kaempferol in treatment of metabolic associated fatty liver disease.
Kaixuan Z; Dong Z; Huiwei B; Lijing LI
J Tradit Chin Med; 2022 Oct; 42(5):788-794. PubMed ID: 36083487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
